Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined non-small cell lung cancer (NSCLC) patients.
Jacques De Greve
No relevant relationships to disclose
Teresa Moran
No relevant relationships to disclose
Marie-Pascale Graas
No relevant relationships to disclose
Daniella Galdermans
No relevant relationships to disclose
Peter Vuylsteke
Other Remuneration - Boehringer Ingelheim
Jean-Luc Canon
No relevant relationships to disclose
Vikram K. Chand
Employment or Leadership Position - Boehringer Ingelheim
Yali Fu
Employment or Leadership Position - Boehringer Ingelheim
Dan Massey
Employment or Leadership Position - Boehringer Ingelheim
Johan Vansteenkiste
No relevant relationships to disclose